5m SBIR Grant for Clinical Trial of SGX942 for Treatment of Oral Mucositis
United States-based Oragenics has dosed the first patient in its phase two clinical trial of AG013 intended for the treatment of oral mucositis
, it was reported yesterday.
is a common and frequently severe complication associated with the damaging effects of radiation on healthy mucosal tissue, usually occurring 2-3 weeks after commencement of radiotherapy.
The incidence of moderate-to-severe oral mucositis
was significantly lower in the active-treatment group than in the control group (20% vs.
The firm said the mouthwash has been developed to prevent oral mucositis
, one of the most common and debilitating complications of chemotherapy and radiation.
Global Markets Direct's, 'Oral Mucositis
- Pipeline Review, H2 2015', provides an overview of the Oral Mucositis
's therapeutic pipeline.
PARK CITY, UTAH -- According to emerging evidence in the medical literature, Mycoplasma pneumoniae-induced rash and mucositis
is a distinct clinical entity with a distinct etiology and a good prognosis.
However, while in vivo animal models of chemotherapy and radiotherapy-induced oral mucositis
have been successfully established, alternative methods such as in vitro tools for mucositis
are still missing.
was given an SBIR award to fund the development of genetically-modified mesenchymal stem cells treated with Targazyme's lead product, TZ101 for treatment of oral mucositis
Background: Anemia and oral mucositis
are main side effects of radiotherapy (RT) and are important factors affecting the quality of life (QOL) in head and neck cancer (HNC) patients treated with RT.
An evidence-based protocol for dental care with specific treatment modalities, including the prevention and treatment of oral mucositis
(OM), is included.
This initial target indication is pain management for patients suffering from oral mucositis
during cancer therapy.